Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets
Authors:
Open Access
- 19 October 2019
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 26 (1) , 1-16
Abstract
Background: Intratumor subsets with tumor-initiating features in glioblastoma are likely to survive treatment. Our goal is to identify the key factor in the process by which cells develop temozolomide (TMZ) resistance. Methods: Resistant cell lines derived from U87MG and A172 were established through long-term co-incubation of TMZ. Primary tumors obtained from patients were maintained as patient-derived xenograft for studies of tumor-initating cell (TIC) features. The cell manifestations were assessed in the gene modulated cells for relevance to drug resistance. Results: Among the mitochondria-related genes in the gene expression databases, superoxide dismutase 2 (SOD2) was a significant factor in resistance and patient survival. SOD2 in the resistant cells functionally determined the cell fate by limiting TMZ-stimulated superoxide reaction and cleavage of caspase-3. Genetic inhibition of the protein led to retrieval of drug effect in mouse study. SOD2 was also associated with the TIC features, which enriched in the resistant cells. The CD133+ specific subsets in the resistant cells exhibited superior superoxide regulation and the SOD2-related caspase-3 reaction. Experiments applying SOD2 modulation showed a positive correlation between the TIC features and the protein expression. Finally, co-treatment with TMZ and the SOD inhibitor sodium diethyldithiocarbamate trihydrate in xenograft mouse models with the TMZ-resistant primary tumor resulted in lower tumor proliferation, longer survival, and less CD133, Bmi-1, and SOD2 expression. Conclusion: SOD2 plays crucial roles in the tumor-initiating features that are related to TMZ resistance. Inhibition of the protein is a potential therapeutic strategy that can be used to enhance the effects of chemotherapy. GraphicalKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 103-2320-B-038-046-MY3, MOST 103-2314-B-400-011-MY3, MOST 108-2314-B-400-026)
- National Health Research Institutes (CA-107-PP-08)
This publication has 52 references indexed in Scilit:
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival AnalysisPLOS ONE, 2013
- Manganese superoxide dismutase depletion in murine hematopoietic stem cells perturbs iron homeostasis, globin switching, and epigenetic control in erythrocyte precursorcellsFree Radical Biology and Medicine, 2013
- A restricted cell population propagates glioblastoma growth after chemotherapyNature, 2012
- Chemoresistance of glioblastoma cancer stem cells - much more complex than expectedMolecular Cancer, 2011
- Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 InhibitionJournal of Biological Chemistry, 2010
- Interaction of Hypoxia-Inducible Factor-1α and Notch Signaling Regulates Medulloblastoma Precursor Proliferation and FateStem Cells, 2010
- Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in GlioblastomaStem Cells, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Association of reactive oxygen species levels and radioresistance in cancer stem cellsNature, 2009
- Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant GliomaStem Cells, 2009